- Home
- ZYME vs THQ Comparison
ZYME vs THQ Comparison
Compare ZYME & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- THQ
- Stock Information
- Founded
- ZYME 2003
- THQ 2014
- Country
- ZYME United States
- THQ United States
- Employees
- ZYME N/A
- THQ N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- THQ Finance Companies
- Sector
- ZYME Health Care
- THQ Finance
- Exchange
- ZYME Nasdaq
- THQ Nasdaq
- Market Cap
- ZYME 983.6M
- THQ 845.7M
- IPO Year
- ZYME 2017
- THQ N/A
- Fundamental
- Price
- ZYME $14.39
- THQ $20.76
- Analyst Decision
- ZYME Buy
- THQ
- Analyst Count
- ZYME 6
- THQ 0
- Target Price
- ZYME $19.17
- THQ N/A
- AVG Volume (30 Days)
- ZYME 340.7K
- THQ 158.9K
- Earning Date
- ZYME 03-05-2025
- THQ 01-01-0001
- Dividend Yield
- ZYME N/A
- THQ 7.53%
- EPS Growth
- ZYME N/A
- THQ N/A
- EPS
- ZYME N/A
- THQ N/A
- Revenue
- ZYME $62,199,000.00
- THQ N/A
- Revenue This Year
- ZYME $21.53
- THQ N/A
- Revenue Next Year
- ZYME N/A
- THQ N/A
- P/E Ratio
- ZYME N/A
- THQ N/A
- Revenue Growth
- ZYME N/A
- THQ N/A
- 52 Week Low
- ZYME $7.97
- THQ $15.29
- 52 Week High
- ZYME $17.70
- THQ $20.38
- Technical
- Relative Strength Index (RSI)
- ZYME 49.88
- THQ 56.80
- Support Level
- ZYME $14.45
- THQ $20.12
- Resistance Level
- ZYME $15.25
- THQ $21.00
- Average True Range (ATR)
- ZYME 0.73
- THQ 0.35
- MACD
- ZYME -0.02
- THQ -0.03
- Stochastic Oscillator
- ZYME 64.58
- THQ 62.14
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.